Abstract
A prospective randomized trial tested the hypothesis that interferon and cytotoxic chemotherapy delivered sequentially would be synergistic and would increase the response rate in metastatic renal cell carcinoma. Thirty-six patients were entered and randomized to chemotherapy only (5-fluorouracil, doxorubicin, mitomycin, and cis-platin) vs. interferon alternating with the same chemotherapy. Only 4 of 32 evaluable patients (13%), 2 in each arm, had a major response. Three patients in the alternating arm had minor responses. Complete, partial, and minor responses totaled 7 (22%). All four patients whose only disease was lung metastasis had some evidence of response (p = 0.001). Interferon alternating with chemotherapy did not appear to improve the major response rate over chemotherapy alone. Responses in metastatic renal cell carcinoma appear confined to a favorable subset of patients.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / therapy*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Interferon Type I / therapeutic use*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / therapy*
-
Mitomycins / administration & dosage
-
Mitomycins / adverse effects
-
Neoplasm Metastasis
-
Prospective Studies
-
Random Allocation
-
Recombinant Proteins
-
Remission Induction
-
Time Factors
Substances
-
Interferon Type I
-
Mitomycins
-
Recombinant Proteins
-
Doxorubicin
-
Cisplatin
-
Fluorouracil